---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-007582"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:48:01.227104+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma terminates Adva-27a research agreement with JGH after unfavorable lab results

## Summary
- Termination of Research Agreement with Jewish General Hospital effective Dec 2, 2023.
- Lab results on Adva-27a molecule were unfavorable, prompting termination.
- IND-enabling studies of Adva-27a are paused pending chemical modification review.
- Company exploring chemical modification to address suboptimal performance in certain studies.
- No financial impact from termination disclosed in the filing.

## SEC filing metadata
- accession: 0001683168-23-007582
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316823007582/0001683168-23-007582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316823007582/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-007582
- JSON: https://secwatch.observer/filing/0001683168-23-007582.json
- Plain text: https://secwatch.observer/filing/0001683168-23-007582.txt

## Key facts
- Material Agreements
  Sunshine Biopharma Inc. terminated Research Agreement with Jewish General Hospital (JGH) valued at termination of Research Agreement for Adva-27a IND-enabling studies (effective 2023-12-02).
  - Action: termination
  - Agreement: collaboration
  - Counterparty: Jewish General Hospital (JGH)
  - Value: termination of Research Agreement for Adva-27a IND-enabling studies
  - Effective: 2023-12-02
  source text: On November 2, 2023, the Company provided notice to JGH of its termination of the Research Agreement, which will become effective on December 2, 2023, pursuant to the terms of the Research Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316823007582/0001683168-23-007582-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.